Author

M. Pierobon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

E. F. Petricoin· 3 shared C. J. Der· 2 shared A. Agarwal· 1 shared A. Barrera· 1 shared A. D. Cox· 1 shared A. E. Stewart· 1 shared A. J. Armstrong· 1 shared A. K. Sood· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. F. Petricoin

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers

D. P. Nussbaum, C. A. Martz, A. M. Waters, A. Barrera, J. C. Rutter, C. G. Cerda-Smith, A. E. Stewart, C. Wu, M. Cakir, C. B. Levandowski, D. E. Kantrowitz, S. J. McCall, M. Pierobon, E. Petricoin, J. J. Smith, , K. C. Wood

This study shows that Mediator kinase inhibition prevents resistance to ERK/MAPK inhibitors in KRAS-mutant cancers by blocking transcriptional plasticity.

bioRxiv · Sep 17, 2022 · PreprintCancer Biology

Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer

J. N. Diehl, J. E. Klomp, K. R. Snare, D. R. Blake, P. S. Hibshman, Z. D. Kaiser, T. S. K. Gilbert, E. Baldelli, M. Pierobon, B. Papke, R. Yang, R. G. Hodge, N. U. Rashid, E. F. Petricoin, L. E. Herring, , C. J. Der

This study identifies upregulated and downregulated kinases in KRAS-mutant pancreatic cancer using chemical proteomics, revealing potential therapeutic targets.

bioRxiv · Apr 27, 2021 · PreprintCancer Biology

Extensive Intratumor Proteogenomic Heterogeneity Revealed by Multiregion Sampling in High-Grade Serous Ovarian Tumor Specimens

A. L. Hunt, N. W. Bateman, W. Barakat, S. Makohon-Moore, B. L. Hood, K. A. Conrads, M. Zhou, V. Calvert, M. Pierobon, J. Loffredo, T. J. Litzi, J. Oliver, D. Mitchell, G. Gist, C. Rojas, , T. P. Conrads

The paper analyzes proteogenomic heterogeneity in ovarian tumors using multiregion sampling and reveals distinct expression patterns between tumor epithelium and stroma.

bioRxiv · Oct 6, 2020 · PreprintCancer Biology

Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes

K. E. Ware, S. Gupta, J. Eng, G. Kemeny, B. J. Puviindran, W.-C. Foo, L. A. Crawford, R. G. Almquist, D. Runyambo, B. C. Thomas, M. U. Sheth, A. Agarwal, M. Pierobon, E. F. Petricoin, D. L. Corcoran, , J. Somarelli

This study identifies p38/MAPK pathway activation as a convergent mechanism driving survival, immune evasion, and metastasis in hormone-resistant prostate cancer.

bioRxiv · Apr 22, 2020 · PreprintCancer Biology